-
A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody
Bolland M , Malaise O , Ribbens C
Rev Med Liege 2023, 78(4),239-244Abstract : Romosozumab (Evenity®) is a humanized monoclonal anti-sclerostin antibody. It represents a major breakthrough in the treatment of osteoporosis: while most treatments inhibit bone resorption, romosozumab has a dual effect, by increasing bone formation and reducing bone resorption. It is reimbursed in postmenopausal osteoporosis in patients with very high fracture risk (i.e. after a recent major fracture, occurring within two years). Its ideal use, in the therapeutic sequence for post-menopausal women, is as first line treatment in case of a recent major fracture. It is contraindicated in case of hypocalcemia and personal history of stroke or myocardial infarction.
